Nicotrol effectiveness in controlling "worst cravings" is substantiated, J&J tells NAD.
This article was originally published in The Tan Sheet
Executive Summary
NICOTROL EFFECTIVENESS IN CONTROLLING "WORST CRAVINGS" is demonstrated in the two large clinical trials submitted to FDA in support of the Rx-to-OTC switch application for the smoking cessation patch, McNeil parent Johnson & Johnson maintains in an April 15 letter to the National Advertising Division of the Council of Better Business Bureaus.